688235:SSEBeOne Medicines Ltd. Class A Analysis

BeOne Medicines AG is trading at CNY 213.9, well below its 20‑day (CNY 236.75), 50‑day (CNY 240.33) and 200‑day (CNY 268.18) moving averages, indicating a sustained bearish price trend. The RSI of 35.3 suggests the stock is approaching oversold territory, yet the MACD remains bearish with the line 3 points under the signal and a negative histogram. Valuation metrics are extreme: a trailing P/E of 92.6 versus an industry average of 24.9, a price‑to‑book of 9.6, and a DCF‑derived fair value of only CNY 26.9 highlight a massive overvaluation. Volatility is high at 46.8% over the past 30 days, though beta is low at 0.40, indicating limited market‑wide systematic risk.
Fundamentally, the company posted 35.5% revenue growth YoY to CNY 5.74 bn, with an impressive 88% gross margin and positive operating cash flow of CNY 1.28 bn. Cash on hand (CNY 4.79 bn) far exceeds debt (CNY 1.15 bn), providing a solid balance sheet. Recent news underscores pipeline momentum, with >60 abstracts accepted at ASCO/EHA 2026 and Q1 product revenue up 34% YoY, driven by a 38% increase in BRUKINSA sales. These drivers support a strong growth narrative despite the current pricing disconnect.